CT-202 Clinical Trials

1 actively recruiting trial

Pipeline

Phase 1: 1

Top Sponsors

Context Therapeutics Inc.1

Indications

Triple Negative Breast Cancer (TNBC)1
Urothelial Cancer1
Colorectal Cancer1
Breast Cancer1
Cancer1

Other1 trial

A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial Cancers

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.